Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer

In non‐small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) significantly improve overall survival (OS). Tumor mutational burden (TMB) has emerged as a predictive biomarker for patients treated with ICIs. Here, we evaluated the predictive power of TMB measured by the Oncomine™ Tumor M...

Descripción completa

Detalles Bibliográficos
Autores principales: Alborelli, Ilaria, Leonards, Katharina, Rothschild, Sacha I, Leuenberger, Laura P, Savic Prince, Spasenija, Mertz, Kirsten D, Poechtrager, Severin, Buess, Martin, Zippelius, Alfred, Läubli, Heinz, Haegele, Jasmin, Tolnay, Markus, Bubendorf, Lukas, Quagliata, Luca, Jermann, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2019
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972587/
https://www.ncbi.nlm.nih.gov/pubmed/31471895
http://dx.doi.org/10.1002/path.5344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972587/
https://www.ncbi.nlm.nih.gov/pubmed/31471895
http://dx.doi.org/10.1002/path.5344

Ejemplares similares